Antonia M. A.
- Country
- Spain
- Department
- Oncology
Research Overview
- Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study
- Efficacy and Safety Evaluation of Olaparib Monotherapy and Olaparib-Durvalumab Combination in Neoadjuvant Treatment of HER2-Negative BRCA-Mutated Breast Cancer
Data & Insights
Has run more than one trial at 16 of 164 partner sites.
Specializations
Breast Cancer Research
Specializes in investigating therapeutic approaches for HER2-negative breast cancer, with particular focus on patients carrying germline BRCA mutations.
- High-risk primary breast cancer management
- BRCA mutation-related oncology
- Adjuvant therapy optimization
Investigates disease-free survival outcomes in breast cancer patients through targeted therapeutic interventions.
Precision Oncology
Focuses on developing personalized treatment strategies for patients with genetic mutations affecting breast cancer progression.
- Targeted therapy applications
- Genetic profiling in oncology
- Treatment response assessment
Explores innovative approaches in mutation-specific cancer treatment protocols.
Treatment Innovation
Advances research in adjuvant therapeutic strategies for breast cancer patients, focusing on improving long-term clinical outcomes.
- Post-primary treatment protocols
- Disease recurrence prevention
- Treatment efficacy evaluation
Studies therapeutic interventions aimed at enhancing invasive disease-free survival rates.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.